8-K: Celcuity Inc. Secures $248.7 Million Through Concurrent Stock and Convertible Notes Offerings

Celcuity Inc. announced the successful pricing and expected closing of concurrent public offerings, raising approximately $248.7 million in net proceeds from common stock, pre-funded warrants, and convertible senior notes to fund its clinical-stage oncology programs.

Summary

• Celcuity Inc. priced a public offering of 1,836,842 shares of common stock at $38.00 per share and pre-funded warrants to purchase up to 400,000 shares of common stock at $37.999 per warrant.
• The underwriters fully exercised their option to purchase an additional 335,526 shares of common stock on July 30, 2025.
• A concurrent offering of $175.0 million aggregate principal amount of 2.750% Convertible Senior Notes due 2031 was also priced.
• The estimated net proceeds from both offerings, after deducting underwriting discounts and offering expenses, are approximately $248.7 million.
• The common stock offering is expected to close on July 31, 2025, and the convertible notes offering on August 1, 2025, with neither offering contingent on the other's closing.
• The Company will irrevocably elect to settle conversions of the Convertible Notes in shares of Common Stock, with cash in lieu of any fractional share.
• The initial conversion rate for the Convertible Notes is 19.4932 shares of Common Stock per $1,000 principal amount, equivalent to an initial conversion price of approximately $51.30 per share, representing a 35% premium over the common stock offering price.
• The Company decided not to enter into initially contemplated capped call transactions in connection with the Convertible Notes Offering.
• Directors and executive officers are subject to a 60-day lock-up period on their securities.

Sentiment

Score: 5

Explanation: The successful capital raise of nearly $250 million is a significant positive for a clinical-stage biotech, providing crucial funding for its pipeline. However, the explicit disclosure of the decision not to pursue capped call transactions and the associated risk of adverse stock price impact due to hedging activities introduces a notable negative element, balancing the overall sentiment to neutral.

Positives

• Successfully raised approximately $248.7 million in net proceeds, significantly bolstering the Company's financial position.
• The capital infusion provides funding for working capital, general corporate purposes, and critical expenditures including clinical trials, research and development, and commercial launch activities.
• The Convertible Notes were priced at a 35% premium to the common stock offering price, indicating investor confidence in the Company's future equity value.
• The Company's lead therapeutic candidate, gedatolisib, is progressing through multiple Phase 3 and Phase 1/2 clinical trials for various oncology indications, demonstrating active pipeline development.

Negatives

• The Company's decision not to enter into capped call transactions for the Convertible Notes Offering could lead to adverse effects on the market price of its Common Stock and Convertible Notes, as investors may now hedge their equity price risk by selling Common Stock or entering into other derivative transactions.

Risks

• The Company's decision not to enter into capped call transactions may lead to investors hedging their equity price risk by selling Common Stock or entering into derivative transactions with other parties, which could adversely affect the market price of the Common Stock and the Convertible Notes.
• Forward-looking statements are subject to substantial risks, uncertainties, assumptions, and changes in circumstances that may cause plans to differ materially, including market risks, trends, and conditions.
• Risks described in the Company's SEC filings, particularly under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, are applicable.

Future Outlook

The Company intends to use the net proceeds from the offerings for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, clinical trial expenditures, commercial launch expenditures, and expansion of business development activities. The Company's lead therapeutic candidate, gedatolisib, is currently being evaluated in ongoing Phase 3 and Phase 1/2 clinical trials for various oncology indications.

Industry Context

This capital raise is typical for a clinical-stage biotechnology company like Celcuity, which requires substantial funding to advance its drug candidates through costly and lengthy clinical trials. The proceeds will support the continued development of gedatolisib, a pan-PI3K and mTORC1/2 inhibitor, in the competitive oncology therapeutic area, particularly for advanced breast cancer and metastatic castration-resistant prostate cancer. The concurrent equity and convertible debt offerings demonstrate a diversified approach to financing R&D and potential commercialization efforts.

Stakeholder Impact

• Shareholders: Potential for dilution from the issuance of new common stock and shares underlying pre-funded warrants and convertible notes. Potential for adverse impact on stock price due to hedging activities by convertible note investors.
• Employees: Continued funding for research and development, and clinical trials, supporting job security and project progression.
• Patients: Continued advancement of clinical trials for targeted oncology therapies, potentially leading to new treatment options.
• Creditors: Issuance of new convertible senior notes adds to the Company's debt obligations.

Next Steps

• Closing of the common stock offering on July 31, 2025.
• Closing of the convertible notes offering on August 1, 2025.
• Application of net proceeds for working capital, general corporate purposes, capital expenditures, research and development, clinical trial expenditures, and commercial launch expenditures.
• Continued enrollment and progression of Phase 3 VIKTORIA-1 and VIKTORIA-2 clinical trials for HR+/HER2advanced breast cancer.
• Continued progression of Phase 1/2 CELC-G-201 clinical trial for metastatic castration resistant prostate cancer.

Key Dates

Recommendation

The significant capital raise provides essential funding for Celcuity's clinical programs, which is a positive for its long-term operational stability. However, the explicit risk associated with the absence of capped call transactions for the convertible notes introduces potential near-term stock price volatility due to hedging activities. Given these offsetting factors, a 'hold' recommendation is prudent, advising investors to monitor the stock's performance and the company's clinical progress closely before making further investment decisions.

Keywords

Celcuity Inc., CELC, Public Offering, Common Stock, Pre-Funded Warrants, Convertible Senior Notes, Capital Raise, Biotechnology, Oncology, Clinical Trials, Gedatolisib, PI3K Inhibitor, mTORC1/2 Inhibitor, Nasdaq, SEC Filing